The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).
Scott N. Gettinger
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Research Funding - ARIAD
Lyudmila Bazhenova
No relevant relationships to disclose
Ravi Salgia
No relevant relationships to disclose
Corey J. Langer
Research Funding - ARIAD
Kathryn A. Gold
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD
Glen J. Weiss
Honoraria - Celgene; Genentech; Medscape; Pfizer; Quintiles
Narayana I. Narasimhan
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
David J. Dorer
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Other Remuneration - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Tim Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Frank G. Haluska
Employment or Leadership Position - ARIAD
Consultant or Advisory Role - ARIAD (I)
Stock Ownership - ARIAD
Honoraria - Lia Gore (I)
Research Funding - ARIAD
D. Ross Camidge
Honoraria - ARIAD
Research Funding - ARIAD